Vaccine World Summit 2011- India

In India
Organizer:- enterprise)

Important Dates

Start Date: 1 March 2011

End Date : 3 March 2011
Eligibility:- Undergrad Level

Type of Opportunity:- Conference/Symposium

Vaccine World Summit India is the LARGEST and ONLY vaccine conference India to bring together Indian and international vaccine industry’s leading players, innovative biotechs, technocrats to showcase latest innovations from discovery to development, from manufacturing to delivery and formulation, and exchange ideas for new strategies and next generation technologies that help facilitate access to new vaccines both in the developing and the developed world, in order to combat global pandemic threats.

Visit the website to register.

Website :

Website of Opportunity:

COP10--Biodiversity / Japan's COP10 plan shows 'leadership'

NAGOYA--Japan's performance as host of the 10th Conference of the Parties to the Convention on Biological Diversity (COP10) in Nagoya has been "historical," CBD Executive Secretary Ahmed Djoghlaf said Friday, praising a last-ditch compromise proposed by Environment Minister and COP10 President Ryu Matsumoto as "living demonstration of leadership."
Djoghlaf spoke in an interview with The Daily Yomiuri soon after the release of a draft decision submitted by Matsumoto for a protocol concerning access and benefit-sharing (ABS) of genetic resources. Prepared in an effort to bridge the gap between still-divided parties on the final day of COP10, the draft included such changes as the removal from the main body of the text numerous disputed references to derivatives of genetic resources and the traditional knowledge of indigenous and local peoples.
However, it also agrees on the establishment of an intergovernmental committee for the ABS protocol that will conduct further negotiations on such issues as "measures to raise awareness of the importance of genetic resources and associated traditional knowledge, and related access and benefit-sharing issues."
"This is a package," the executive secretary said. "This is the draft, but you have a process to continue the negotiations. We cannot solve everything overnight; this is a very complex issue."
"Really, I want to pay tribute to Japan, whatever I can say to thank the government of Japan, the people of Japan," he said. "This text is a living demonstration of leadership."
Djoghlaf said he expected the COP10 parties to agree to the draft decision and had harsh words for any who might block it: "Whoever will disagree means that he doesn't want the protocol, because it's a fair compromise. Whoever will have an objection will bear a historical responsibility, because the person or the group or the country will be responsible for the failure."
"Instead of rushing and posing a decision which will never be implemented, or taking 20 years like the Law of the Sea to be ratified, this protocol will be ratified within two years, which is also part of the package," he said.
"We want to have the first COP-MOP [Meeting of the Parties to the Protocol] back to back with COP11, which will be historical. Meanwhile, we will have the signature of the protocol in New York on the 2nd of February, which will coincide with the launch of the [U.N.] International Year of Forests. The first meeting of the preparatory committee will be in June, not 2020: June next year."
A native of Algeria, Djoghlaf became executive secretary of the CBD in 2006, having previously served as assistant executive director of the U.N. Environment Programme.
He praised the efforts made by many different segments of Japanese society during the conference, including legislators and members of the business community. Among those Djoghlaf mentioned was Nagoya Mayor Takashi Kawamura for his part in the City Biodiversity Summit 2010, a gathering of leaders from more than 200 local authorities around the world, held concurrently with COP10 from Sunday to Tuesday.
Participants adopted a declaration that was submitted to the high-level segment of the conference, pledging support for their respective governments in implementing at the local level the objectives of the CBD and other multilateral environmental agreements related to biodiversity.
Djoghlaf also reiterated the economic value of safeguarding biodiversity, a key theme of the Nagoya conference. Until recently, he said, scientists or nongovernmental organizations met together and "preach[ed] among the converted that biodiversity is important. For the first time, we have also brought the other side of the problem, because the green aspect of biodiversity is known but the economic aspect is undermined."
"You can create a job for two or three years" by depleting natural resources, he said, "but the companies that are destroying the environment will close.
"The green economy takes time, but it's sustainable and it's long-term."
(Oct. 30, 2010)
Heather Howard / Daily Yomiuri Staff Writer

International Confrence on Cell Signaling And Diseases


OrganizerKIIT University(University)

Important Dates

Start Date: 29 October 2010

End Date : 30 October 2010

Eligibility Undergrad Level,Grad Level,Postgrad Level

Type of Opportunity

International Conference on "Cell Signaling and Diseases". Organized by KIIT School of Biotechnology,KIIT University, Bhubaneswar, Orissa, India.

The focus of the conference is to bring together academicians, researchers, students and practitioners under a common umbrella during the two-day meet, so that each one on the platform gains and understands the research needs and expertise of the other person, thus cultivating a culture of inter-institutional team work. The main focus will be on infection biology and emerging diseases, cell signaling, genomics, and proteomics. The conference program includes keynote address, invited talks and oral and poster presentation sessions

Call for Abstracts

Abstracts of original research work in the above mentioned and related areas are invited from scientists, postdoctoral and doctoral researchers worldwide to be considered for oral and poster presentations. Abstracts no longer than 500 words should be submitted in MS word and should include title, name(s) of the author(s) and preference as to the mode of presentation – oral or poster. Abstracts will be peer reviewed and the decision of the organizing committee shall be final. Posters should conform to the suggested size of 4’ X 3’ and include title (Capital letters, font Arial; size 12), author names (font Arial; size 12) with presenting author name underlined and address for communication (font arial; size 11). Once accepted, notification will be provided by email to the presenting author. The presenter must register for conference for paying the applicable registration fee.

Inaugural talk by Prof. Iain Mattaj

Director General

European Molecular Biology Laboratory (EMBL)

Heidelberg, Germany

Conference Secretariat

Dr. Mrutyunjay Suar, Conference Organizing Secretary,

KIIT School of Biotechnology (KSBT), Campus-11,

KIIT University, Patia, Bhubaneswar-751024, INDIA

Phone: +91 674 2725732, +91 9437011465 Fax: +91 674 2725732 for registration details visit this page http://www. kiitbiotech. ac. in/intcon/re. htm

Website :
Website of Opportunity:

RASA life Science Informatics

RASA Life Science Informatics, a bio-Chemoinformatics company based in Pune. Equipped with team members having a combined experience of more than 150 years, RASA is ready to set a new benchmark in providing services and solutions in the domain of bioinformatics, chemoinformatics and life science software development. RASA believes in sharing knowledge, hence we have a dedicated training division wherein students and professionals are trained.

Ø RASA is a pioneer in providing ’in demand ’ job & research oriented training & projects.

Ø RASA have successfully trained scientist and professionals from NCL, NARI , Persistent, Evolves, D Y patil, and other reputed national institutes & companies.

Ø RASA trained biochemistry, microbiology, biotech students in bio/ Chemoinformatics & pharmacoinformatics to enhance & optimize their research & publication work.

Ø RASA audience pool ranges from Junior college to PhD holders.

Ø 90% students get placed after training from RASA across India & abroad in various Pharma , biotech,CRO, institutes & companies like Xceleris, Evolvus, NCL & in RASA itself.

Ø RASA facilitate Corporate Training to reputed companies.

Why Industrial Training?

· To meet corporate/research need to get hire easily.

· To channelize efforts in right direction.

· To optimize knowledge and skills.

· To be out performer from day one on work.

Industrial Training & Projects Details :

RASA provide summer/winter/industrial training, certification courses and projects of duration 1 month to 6 months in field of Bioinformatics/Chemoinformatics & Biotech. Topics are as follows.

RASA‘s Exclusive training modules & projects topics :

v Micro-Array data Analysis,

v Protein Crystallography data Analysis

v Workflow Development

v QSAR studies

v in-Silico Primer designing and gene cloning

v virtual Library designing and scaffold hopping

v Life science software development

v Ligand based drug designing

v Structure based drug designing

v homology Modeling and Docking

v Bioinformatics

v Chemoinformatics /pharmacoinformatics


v Database Development

v Perl/Python/BioPerl/BioPython

v Life science portal/tool development

Biotech Training & Projects :

The project will have both Biotechnology and Bioinformatics topics, thus enabling you to have an increased level of understanding on your project. Duration is 6 months.

1. Industrial Training & project in Recombinant DNA Technology

2. Industrial Training & project in Cancer Cell Culture

Salient Features of RASA Training& Projects :

Ø We intent to restrict maximum number of students to 15 only.

Ø Chances to publish papers.

Ø Batches start every month.

Ø We conduct batches on week ends also.

Ø Guest lecture & guidance from eminent scientist from research institute of India and abroad.

Audience: Any one from junior college students, Diploma holders ,Graduates, Post-Graduates ,PhD holder, Teachers, scientist ,professional of science background like bioinformatics, chemistry, Pharma, biotech, microbiology, biochemistry etc. Those who want to meet industry standards.

Speakers: RASA teaching members are having experienced more than 50 years in industry and research organization. Some of RASA speakers are as follows:

National Speakers :

v Aftab Ahmed Khan (MD of RASA,5 yrs exp in Bio-&Chemoinformatics)

v Sapana Mehendale (M D, RASA,4 yrs exp in life science software development)

v Dr. Muthukumarasamy Karthikeyan (Scientist E1,NCL,15 yrs exp in Chemoinformatics & Drug Discovery Research)

v Dr. Rajesh Kumar Singh (Scientist,NCL,15 yrs exp in Molecular Biology, Biotech, protein crystallography )

v Dr. Syed Ismail Ahson (Pro VC, Patna University,55 yrs exp in Computer science Bio/Chemoinformatics)

v Pradeep Malji (Engineer, KSB Tech Pvt. Ltd, 4 years exp Software Design and Development, Technical Support)

v Saurabh Bundela (Senior Scientist, Systems Biology Worldwide,11 yrs exp in Genomics, proteomics, Bioinformatics)

v Vishal Rajdev(Senior S/w Executive, Thermax,6 yrs exp in Database management & ERP)

v Surojit Sadhu(Jr. Application Scientist, RASA,1.5 yrs exp in Bioinformatics/Chemoinformatics)

International Speakers:

v Dr.Alexander Tropsha(Professor and Chair UNC , USA, 26 yrs exp in Drug Discovery)

v Dr.Andreas Bender(Lecturer, University of Cambridge,UK,15 yrs exp in chemo/pharmacoinformatics)

v Dr.Santosh Panjikar(Scientist, EMBL-Hamburg, Germany,10 yrs exp in Protein crystallography )

v Dilip Narayana (Pursuing PhD ,Norway,5 yrs in Chemo-informatics)




RASA Life Science Informatics ,

opp Chitaranjan vatika, Model colony,Shivaji nagar,

Pune 411016.

Phone : 020 – 65600408,08007594458

Indo-US Research Fellowships

Indo-US Research Fellowships For Indian Researchers

In an effort to augment scientific excellence in erne rging areas of science and technology, the indo-US Science and Technology Forum (IUSSTF) In association with Science and Engl neering Research Council (SERC) of Department of Science and Technology (DST), announces the Indo-US Research Fellowships for the year 2011. The objective of the fellowship is to enable young researchers from India to carry out research in frontier areas of science and technology at a premier institution in USA. The fellowship will enable early and mid career Indian researchers to acquaint themselves with new scientific research methods and at the same time build strong collaborative linkages between the scientific communities of US and India.

Eligibility/ Application Requirements

Academic Qualifications

Master's Degree in Engineering, Technology or equivalent or Ph. D. In Science or Technology or equivalent or M. D. Degree in Medicine or equivalent Applicants must provide proof of independent research work in internationally recognized academic journals

Age : Upto 40 years as on 31 December 2010


A permanent position in a public funded R&D lab/ S&T institution (non-private)/ recognized universities/colleges in India
Areas covered under the Fellowship

* Atmospheric and Earth Sciences

* Chemical Sciences

* Engineering Sciences

* Life Sciences

* Medical Sciences

* Mathematical and Computational Sciences

* Physical Sciences

Promising applications in areas other than the above areas may also be considered
Place of work

The applicant should have letter of acceptance from reputed US scientific/technological institution where the applicant will be undertaking the research work under the Fellowship.

Fellowship Includes

• Monthly stipend

• Return airfare

• Preparatory allowances

• Conference allowances

Fellowship Duration

Minimum 3 months and upto 12 months


Dr. Smriti Trikha

Indo-US Science and Technology Forum

12 Hailey Road, Fulbright House, New Delhi-110 001

Website :

Fee Of Biotecnology In Europe

Fee Of Biotecnology In Europe

Beasiswa Scholarships

Phd scholarship in Sociology for the year 2011 from googlecom; 3rd merit list of bsc engineering 2010 from googlecom; fee of biotecnology in europe from ...

Microbial biotecnology powerpoint download and Microbial

Microbial biotecnology powerpoint download and Microbial ...

Download microbial biotecnology powerpoint and Download microbial biotecnology ppt - on

Nanotech India 2010

Welcome to Nanotech India 2010 (19th - 21st November 2010 )

Nanotechnology has finally gained recognition in India. As an attempt to place India on the global Nanotechnology map, an Annual Conference and Business Meet in Nanotechnology begins today right here in Cochin, the commercial hub of the state of Kerala, from 19th–21st November 2010. Titled Nanotech India 2010, this conference is aimed at pulling together industry leaders, researchers, entrepreneurs and investors to create a platform for discussion on the issues and opportunities that are vital in commercializing Nanotech innovations. It is no wonder then that this conference has emerged as the premier nanotechnology research and business event in India.

workshop on Nanobioinformatics:Nano Goes insilico

The Bioinformatica Solutions of Lucknow based organization that is going to organize a three day workshop on:

Informatics explores"Room at the bottom":Nano Goes insilico

The Lectures will be delivered by the experts from different research center. Interested students can apply on to get the full detailed information about the workshop.

2006 Wang Marine Biotecnology Discovery of the Genes in Response to White Spot Syndrome

International Conference on Emerging Frontiers and Challenges in HIV/AIDS Research

National Institute for Research in Reproductive Health (Indian Council of Medical Research) and Indian Society for the Study of Reproduction and Fertility Mumbai

The International Conference on “Emerging Frontiers and Challenges in HIV/AIDS Research” aims to provide an interactive forum to the researchers who have been engaged in addressing the cutting edge
researchable issues such as mode and mechanism of HIV infection and transmission; resistance to the pathogen as well as anti-HIV drugs; disease progression; and development of efficacious strategies for
prevention, diagnosis and treatment of HIV/AIDS.

The meeting will dwell on the key roadblocks to translational research in the field of HIV/AIDS which includes inconclusive knowledge of the basic mechanism of HIV pathogenesis, nature of the cellular and
anatomical reserviores of virus infection, limitation of non human primate models and lack of consensus in the appropriate models for vaccine research and product testing. Special sessions on the policymaking and advocacy for the programmes on control and management of HIV/AIDS will be the other highlights of this international meet.

This meeting is expected to create an excellent convergence of the perspectives of those with specific interests in fundamental, clinical and sociobehavioural research on HIV/AIDS. We earnestly hope that the deliberations during the conference will help in translating theoretical advances into the clinical practices and contribute towards deaccelerating the pace of this pandemic.

The scientific programme will include plenary lectures, lectures from invited speakers and oral /poster sessions covering the following major themes

Basic Research

Clinical Research

Socio-behavioral Research

Submission of Abstract

The abstract of about 300 words typed on a plain paper using Microsoftword (12pt,Times New Roman) to be sent by email to the Organizing Secretary by

November 30,2010

UCD team discovers genetic link to blood clots

Research reveals genetic markers which identify why some people are prone to heart attacks

IRISH SCIENTISTS have spearheaded a major breakthrough in understanding why some people are more prone to developing potentially fatal blood clots.

A team from the Conway Institute at University College Dublin, working in collaboration with a Europe-wide consortium, has uncovered a series of genetic markers which identify people at risk of excessive clot formation and heart attack.

The research, published in the leading haematology journal Blood , is predicted to advance radically the detection and treatment of coronary artery disease (CAD), the most common cause of premature death in Ireland.

Heart attacks normally arise from clots in the coronary artery. The clotting mechanism is initiated by platelets, tiny cellular particles that float in the bloodstream. When bleeding occurs, chemical reactions change the surface of the platelets to make them sticky, enabling them to fuse together on the surface of blood cells and form a clot.

It has long been observed that the level of platelet activity and clot formation vary considerably from person to person, partly as a result of their genetic make-up.

As part of the European Union’s Bloodomics project, the UCD team investigated the complex genetic pathways involved in platelet activity to understand better how they are involved in heart disease. The team managed to link, for the first time, a number of the 60 or so genetic variants associated platelet activity to an increased risk of heart attack.

“Essentially, we have found the genetic traits that promote clot formation in people who have a history of heart disease,” said biochemist Dr Patricia Maguire, who jointly led the UCD team’s work alongside professor of molecular medicine and vice-president for research at the university, Desmond Fitzgerald.

Identifying the at-risk category at an early stage should enable doctors to prevent people developing CAD through lifestyle changes and/or medication, she said.

Separate from the research, published this month, the UCD team has also uncovered a specific pathway, not observed before, which dampens down platelet activity.

While anti-clotting drugs such as aspirin have been used by physicians to treat people at risk from heart attack since the 1980s, the drugs do not appear to work on a significant subset of patients. Dr Maguire believes the discovery of a specific pathway which lessens platelet activity may play an important role in the development of new drugs to treat heart disease.

According to figures from the Irish Heart Foundation, cardiovascular disease, which includes CAD and stroke, is the principal cause of mortality in more than 35 per cent of all Irish deaths – about 10,000 lives every year. CAD accounts for nearly half of these deaths, making it the single biggest cause of mortality in Irish men and women.

The UCD team’s research was funded jointly by the European Union and Irish Health Research Board.

Daksh 2010,Social B-Plan Contest,IIFM Bhopal

2 week left!!!

Orgainsed by:- Indian Institute of Foreign Management

Start Date: 13 November 2010

End Date : 13 November 2010
Deadline: 14 October 2010

Eligibility for  Competition/Contest:- Grad Level,Postgrad Level

Indian Institute of Forest Management is a premier sectoral management Institute, which aims at carving out socially responsible managers. The Entrepreneurship Development Cell (EDC), IIFM is organizing a National level Entrepreneurship Summit and DAKSH-10 the Social Business Plan competition on 13th November 2010. Summit will see the participation from well renowned personalities from the field of banking and development and Entrepreneurs discussing their path to success.

We are inviting entries for the Social B-Plan competition.

The participants can choose the area of their interests. Some of the suggested areas are:

 Agribusiness

 Clean/Green Energy

 Eco-Tourism

 Information and Communication Technology (ICT) in Rural Development

 Rural Enterprise Development  Marketing and Supply Chain management

 Any other idea which shows a societal perspective

Size of team: 1 or 2 Management graduates, Engineering graduates and start-ups are eligible to participate

Last date of Registration and submitting Executive Summary is 14th Oct, 2010.

Register at: www. edciifm. com/registration
Prizes worth Rs. 50,000 to be won For more details logon to http://www.%20edciifm.%20com/


Bio technology is a new term evolved in the 20 the century. It is the scientific manipulation of living organism for human benefit and its best known form is genetic engineering, industrial agriculture, plant breeding, animal breeding are the backgrounds of biotechnology. In simple biotechnology brings together technology with the science of the living cells. This paper is focused on the role of patents in the area of Biotecnology, an important tool to protect Biotechnological inventions


Trips that came into force in 1995, provides the minimum standard of patent protection that requires mandatory compliance by all the member countries.Art.27 (3) (b) of TRIPS states that members may also exclude from patentability: plants and animals other than micro-organisms, and essentially biological process for the production of plants and animals other than micro-organisms, and essentially biological process for the production of plants and animals other than non-biological and micro-biological process.However,members shall provide for the protection of plant varieties either by patent or by an effective sui-generis system or by any combination thereof.

The patent protection is obtainable for most of the bio-technological innovations. The protection thus provided serves as an incentive for the further development and technical innovations. Accepting the traditional approach the new premise of patent law state that natural life is the creation of god but the non natural life is the creation of human being. So the new idea of patent law is that creation of god or the creation of the nature could not be patented, where as creations of man which involves the applications of human intelligence to natural things could be patentable.

Art 27 of the TRIPS Agreement forms the basis for the provisions on the patentability of micro-organism. Nevertheless, micro-organisms also have to satisfy the novelty, utility and non-obviousness criteria to be patentable. However, TRIPS agreement does not provide a precise definition of the term micro-organism. The term is generally understood to include viruses, bacteria, yeast and other forms of fungi Protozoa and unicellular algae and non differentiated animal or plant cells. Even though micro-organisms can be patented as per TRIPS agreement; one is often faced with a dilemma whether at all micro-organism constitute a patentable subject matter since they are real life forms.
                                                      The law which opened the gates for inventions in the field of biotechnology, particularly in micro organism, was a land marked judgement of the US Supreme Court in 19809 in diamond v.chakaravarty.The dispute was with regard to a modified micro organism developed by the Anada Chakravarty which has the ability of breaking down the crude oil. This property introduced into the naturally occurring bacterium to produce a genetically modified organism. The commissioner of patent in the US field held that the subject matter of the invention was a living organism and was hence not patentable. The US Supreme Court judge, however, decided in favour of the patentee and stated that everything under sun is patentable. The landmark judgement paved the way for the grant of a number of such biotechnology related patents.
                          In India the position of patentability of the micro-organism is parallel to that of the UK and Europe. The Calcutta high court gave a path breaking judgement in the case of dimminico A.G v.controller of patents and designs which has been hailed in the Indian counter to Diamond V.Chakravarty of the U.S.A.The case related to the patentability of a process for preparation of bursitis vaccine useful for the protecting poultry against the infectious bursities.The ground for rejection of the patent by the controller was that the examiner found that the claim did not fall within sec.2(1)(j) of Indian patent Act,1970 and therefore is not an invention. The court held that ‘merely because the end product of process contains a living organism does not preclude the process from being an invention and consequently patentable.”Further, the court found that the patent claimed was useful as it protected poultry against contagious disease and the end product resulted in a new article.

The TRIPS agreement provides that the member states may exclude plants and animals from patentability. This option has been adopted by a number of countries such as the United Kingdom, Europe and India. The issue of the patentability of animals arises mainly because the patentability of animals is considered to be moral issue rather than a legal one. In India the plant varieties may be protected under the protection of Plant Varieties and Farmer’s       Rights act. This act will come into force soon for the protection of plant variety as it is a requirement under the TRIPS agreement. Inventions which concern plants and animals may be patentable if the technical feasibility of the invention is not confined t o a particular plant or animal variety. The onco-mouse case showed that the exclusion is confined to varieties of animal alone. The EPO applied examinee of animals which subdivides a species into subspecies and varieties. Varieties constitute the lowest sub-division .although the invention was to be applied to mice, any non-human mammal was claimed .As this did not confine the claims to a variety, the patent was granted.
Another aspect which is important to consider under biotechnology is patentability of genes and DNA sequences. Genetic inventions encompasses medical. Agricultural environmental and industrial application patenting of genes would be essential since it would provide an incentive for the manufacture of new and important therapeutic drugs and its application in different areas of biotechnology. The trend of granting patent on non-natural loving being took an interesting turn which claims patent on human genetic material. In john Moor’s case, patent was granted to cell lines of human beings useful in producing cancer fighting protein, followed by patent on human genetic materials like D NA and RNA in amezen Ins vs. Chuga Pharmaceuticals. After this case, European patent office also started granting patents on human genetic material. So it through many case laws that DNA, RNA and human cells could be patented. At the same time it was also made clear that human beings though genetically engineering or none naturally produced could not be patented.

 Non natural or genetically modified living beings are the results of non natural and genetically modified biological processes. Addition of human intelligent to the natural processes renders it non natural. Since patents are available to the products as well as processes, so the task ahead for the inventor of the biological processes was to convince the patent office that biotechnological processes are non natural and there is a role of human agency which differentiate a human process and natural process. In Hybertech Inc Vs Monoclonal Antibodies Inc, a patent was claimed for process of utilising protein to fight against the diseases. The inventors convinced the court that the method is non natural process. Since it utilise proteins produced inside the body on human prescription and obtained patent.
The current trend in the patent however states that the non natural life, living beings and non natural living processes are patentable. Biotechnological processes and micro biological processes are non natural processes which involve addition of human intelligence to the natural process in producing none natural and genetically modified living beings. The inventions of biotechnology ranges from non natural micro organisms like bacteria plasmid, non natural plant, non natural animal and non natural human genetic material which are undoubtedly patentable. Besides, biotechnological process could also be patented in the upsurge of the new period in patent law.